Selecta and Genethon Collaborate to Create Next Generation Gene Therapies Using Selecta’s Synthetic Vaccine Particle Platform

Watertown, Mass., USA, and Evry, France – May 13, 2015 – Selecta Biosciences, Inc. and Genethon today announced an ongoing research collaboration with the goal of enabling repeat dosing for gene therapies. Based on preliminary results, the companies have identified three applications that might benefit from combining Généthon’s expertise in the development of gene therapy vectors and Selecta’s Synthetic Vaccine Particle (SVP™) platform to prevent undesired immune responses. The companies plan to co-develop and co-own these next generation gene therapies, each with the potential to meet significant unmet patient needs.